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Background: Yes-associated protein 1 (YAP1) is a transcription factor regulated by the
Hippo pathway and functions as an oncogene in various solid tumors under dysregulated
Hippo pathway. However, the role of YAP1 in breast cancer remains controversial. Here,
we investigated the impact of different levels of nuclear YAP1 expression on the clinical
characteristics and survival outcome in patients with breast cancer.
Patients and Methods: Retrospectively obtained 455 breast tumor samples at Gangnam
Severance Hospital were examined for YAP1 expression by immunohistochemistry, and the
clinical data were analyzed. External validation was performed using a retrospective cohort and
tissues in 482 patients from Severance Hospital.
Results: High nuclear YAP1 expression was associated with hormone receptor negativity
and aggressive tumor behavior, including lymph node metastasis, high Ki67 labeling index
and inferior distant metastasis-free survival (DMFS, hazard ratio [HR] 2.271, 95%
confidence intervals [CIs] 1.109–4.650, P = 0.0249), and also confirmed inferior
disease free survival (HR 3.208, 95% CIs 1.313–7.833, P = 0.0105) in external
validation cohort. In patients with triple-negative breast cancer (TNBC), high nuclear
YAP1 expression was an independent significant determinant of poor DMFS (HR 2.384,
95% CIs 1.055–5.386, P = 0.0367).February 2021 | Volume 11 | Article 6097431
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prognosis and a potential therapeutic target in patients with breast cancer, especially in TNBC.Keywords: Yes-associated protein 1, breast cancer, prognosis, metastasis, triple-negative breast cancerBACKGROUND
Breast cancer is the most common cancer among women
worldwide, and approximately 15 million people are diagnosed
with this disease each year. In recent years, owing to advanced
treatment modalities and the identification of new drug targets,
breast cancer mortality has decreased by approximately 2.3% per
year (1). So far, well known biomarkers such as including ER and
HER2, as well as others, including pSTAT3 expression, LDH,
and tumor-infiltrating lymphocytes, etc. – have been studied to
elucidate breast cancer biology and survival outcome (2–4),
further endeavor is still required to understand tumor nature.
Despite these improvements, metastatic breast cancer still results
in poor survival. In order to further enhance treatment efficacy,
new drug targets with specific roles in metastatic cascades must
be unveiled.
Lymph node metastasis is the most important prognostic factor
in breast cancer, and is associated with high relapse and mortality
(5–8). The mechanisms underlying lymph node metastasis are still
poorly understood. It has been reported that the transcriptional co-
activator, Yes-associated protein 1 (YAP1), plays an important role
in lymph node metastasis (9). Enhanced YAP1 activity increases
fatty acid oxidation, ultimately leading to lymph node metastasis.
TheHippo signaling regulates organ size and development (10), and
restricts transcription co-factor YAP1 and transcriptional
coactivator with PDZ-binding motif (TAZ) by cytoplasmic
retention followed by protein degradation (11). However,
dysregulated Hippo signaling results in the nuclear accumulation
of non-phosphorylated YAP1 and TAZ. These interact with
transcriptional enhanced associated domain (TEAD)-containing
transcription factors in nucleus, promoting the expression of
genes related to cell proliferation and epithelial-mesenchymal
transition (EMT) (12, 13). Moreover, YAP1 was reported to
induce TEAD-dependent focal adhesion kinase phosphorylation,
ultimately promoting tumor invasiveness (14). Activated YAP1
contributes to cancer development by promoting a malignant
tumor phenotype. In particular, YAP1 stimulates cancer stem cell
proliferation and epithelial-mesenchymal transition, induces drug
resistance, inhibits apoptosis, and promotes tumor overgrowth (10,
15–18). Several studies have reported a correlation of YAP1
expression with aggressive clinical characteristics and low survival
(19–29). This evidence suggests that YAP1 is a potential therapeutic
target, and that its pharmacologic or genetic inactivation may
suppress tumor progression and improve drug sensitivity.
However, the association between clinical data and YAP1
expression in patients with breast cancer has been poorly
explored. In addition, the possible clinical relevance of YAP1
subcellular localization is not clearly defined.
The aim of this study was to correlation between the level of
nuclear YAP1 expression and the clinical characteristics andin.org 2survival rates of patients with breast cancer. The impact of YAP1
expression on survival was also evaluated in patients with triple
negative breast cancer (TNBC).MATERIALS AND METHODS
Patients
We retrospectively collected the tumor tissues from the patients
undergoing primary curative surgery for breast cancer at the
Gangnam Severance Hospital in Seoul, Korea from February
1992 to April 2017 and at the Severance Hospital in Seoul, Korea
from January 2000 to December 2010. A validation cohort
consisted of 482 patients from the Severance Hospital.
Inclusion and exclusion criteria were as follows:
1) Inclusion criteria:
- Patients age ≥ 20 years
- Breast cancer confirmed by pathologic diagnosis (stage I–
III)
- Available YAP1 immunohistochemical staining with tissue
microarray
2) Exclusion criteria:
- Any other carcinoma in situ
- Other cancer history (except thyroid cancer and carcinoma
in situ)
- Not assessable electronic medical record
All subjects were diagnosed with stage I–III primary breast
cancer. All patient treatments were performed according to
standard protocols. The following data were collected: age at
surgery, tumor size, lymph node status, histological grade (HG),
status of estrogen receptor (ER), status of progesterone receptor
(PR), status of human epidermal growth factor receptor-2
(HER2), lymphovascular invasion (LVI), Ki67 leveling index,
tumor-infiltrating lymphocytes (TILs), treatment modalities,
recurrence, and death. Tumor HG was determined by applying
the modified Scarff-Bloom-Richardson grading system. The
study protocol was approved by the institutional review board
(IRB) of the Gangnam Severance Hospital (local IRB No. 3-2019-
0188). The need for informed consent was waived under the
approval of the IRB due to the retrospective design.IMMUNOHISTOCHEMISTRY (IHC)
AND MOLECULAR SUBTYPING
As previously described (30), 3-µm thick tissue sections were cut
from formalin-fixed paraffin-embedded (FFPE) tissue
microarray (TMA) blocks. After deparaffinization andFebruary 2021 | Volume 11 | Article 609743
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respectively, IHC was performed by using a Ventana Discovery
XT Automated Slide Stainer (Ventana Medical System, Tucson,
AZ, USA). Cell Conditioning 1 (CC1) buffer (citrate buffer, pH
6.0; Ventana Medical System) was used for antigen retrieval. The
appropriate positive and negative controls were included.
IHC staining was evaluated with light microscopy (BX53
upright microscope, Olympus, Tokyo, Japan). Nuclear staining
values of 1% or higher were considered indicative of ER (clone
SP1; dilution 1:100; Thermo Scientific, San Diego, CA, USA) and
PR (clone PgR; dilution 1:50; DAKO, Glostrup, Denmark)
positivity (31). HER2 (polyclonal; dilution 1:1500; DAKO)
staining was interpreted based on the 2018 American Society
of Clinical Oncology/College of American Pathologists
guidelines (32). Only samples with strong and circumferential
membranous HER2 immunoreactivity (3+) were considered
positive, while those with 0 and 1+ HER2 staining were
considered negative. Cases with equivocal HER2 expression
(2+) were further evaluated for HER-2 gene amplification by
silver in situ hybridization (SISH). Positive nuclear Ki-67 (clone
MIB; dilution 1:1,000; Abcam, Cambridge, UK) staining was
assessed based on the percentage of positive tumor cells, defined
as Ki-67 labeling index.
The specimens were categorized as follows: i) Luminal/HER2-
negative (ER- and/or PR-positive and HER2-negative); ii) HER2-
positive (HER2-positive regardless of ER and PR status); iii) TNBC
(ER-, PR-, and HER2-negative).EVALUATION OF NUCLEAR YAP1
EXPRESSION BY TISSUE MICROARRAY
AND IHC STAINING
Hematoxylin and eosin-stained slides from the resected breast
cancer specimens were examined, and the representative areas
were marked. The matched tissue cores (2 mm) were extracted
from FFPE tumor blocks and placed into 5 × 10 recipient
TMA blocks.
For IHC, each TMA slide was stained with anti-YAP1 antibody
(clone 63.7; dilution 1:200; Santa Cruz Biotechnology, Dallas, TX,
USA). After staining, nuclear YAP1 expression was assessed by a
pathologist (400×magnification). YAP1 expression was evaluated in
both the cytoplasm and nuclei of the tumor cells. Cytoplasmic
staining was evaluated by the H-score, which was obtained by
multiplying staining intensity (0, 1, 2, or 3) by percentage of stained
area (%). As nuclear expression was rare and mostly focal, only the
intensity of nuclear staining was examined (0, 1+, 2+, 3+), regardless
of the corresponding cytoplasmic staining. The intensity of nuclear
staining of the myoepithelial cells was assigned a value of 2+ and
used as an internal control. Weaker and stronger signals were
assigned a value of 1+ and 3+, respectively. Negative and weak (1+)
nuclear staining were considered indicative of low expression, while
moderate (2+) and strong (3+) nuclear expression were indicative of
high expression (Figure 1). The IHC results were interpreted
blindly, without any information regarding clinical parameters
or outcomes.Frontiers in Oncology | www.frontiersin.org 3STATISTICAL ANALYSIS
Distant metastasis-free survival (DMFS) was defined as the time
from the primary curative surgery to the first breast cancer-
derived distant metastasis, or death due to any cause, or end of
follow-up. Overall survival (OS) was defined as the time from the
primary curative surgery to the end of follow-up, or death due to
any cause. Disease-free survival (DFS) was defined as the time
from the primary curative surgery to cancer recurrence, second
cancer, or death. The data of patients who did not exhibit
relevant events were censored at the end of follow-up.
The continuous variables between the two groups were
compared using the Student’s t-test or the Mann-Whitney test.
The categorical variables were compared by using the Chi-square
test or the Fisher’s exact test. Survival curves were obtained by the
Kaplan-Meier method and two-group comparisons were made
using log-rank test. Univariate and multivariate Cox proportional
hazard models were used to identify the factors associated with
survival outcome (DMFS and OS). The variables showing
statistically significant differences in the univariate analysis were
used in the multivariate Cox proportional hazard models.
Statistical analysis was performed by using SPSS version 24 (SPSS:
Chicago, IL, USA) software. The threshold for statistical significance
was set at P <0.05, with a 95% confidence interval not including 1.RESULTS
Impact of Nuclear YAP1 Expression
on the Baseline Characteristics of
Patients With Breast Cancer
A total of 455 breast cancer patients at Gangnam Severance
Hospital were included in this study. The median age was 50
(25–86) years. The median DFS and OS were 59 (10–325) and 60
(12–325) months. Low and high nuclear YAP1 expression were
found in the tumors of 344 (75.6%) and 111 (24.4%) patients,
respectively. The clinical characteristics were examined in relation to
nuclear YAP1 expression (Table 1). High nuclear YAP1 expression
was associated with aggressive tumor features, including hormone
receptor negativity, high HG, lymph node metastasis, and high Ki67
expression. Patients were classified into three subtypes based on
IHC analysis: luminal/HER2-negative (243 patients), HER2-positive
(62 patients), and TNBC (146 patients). High nuclear YAP1
expression was associated with the TNBC subtype.
Validation cohort included 482 patients at Severance
Hospital. Median DFS and OS were 65 (5–139) and 65 (12–
241) months. Of the 482 patients, 428 (88.8%) exhibited low
nuclear YAP1 expression, and 54 (11.2%) exhibited high nuclear
YAP1 expression. Clinical characteristics were compared to
nuclear YAP1 expression in Supplementary Table 1. Also,
high nuclear YAP1 expression was related to TNBC subtype.
Prognostic Significance of Nuclear
YAP1 Expression
There were 41 patients with developing distant metastasis.
Among them, 14 had bone metastasis, 11 lung metastasis, fiveFebruary 2021 | Volume 11 | Article 609743
Cha et al. YAP1 Expression in Breast Cancerliver metastasis, three brain metastasis, while 17 had developed
metastases to other sites (including duplication). There were 18
mortality events. High nuclear YAP1 expression was significantly
associated with decreased distant metastasis-free survival
(DMSF) [Figure 2A; hazard ratio (HR), 2.271, 95% confidence
intervals (CIs) 1.109–4.650, P = 0.0249, log rank test], and was a
significant predictor of poor overall survival (Figure 2B; HR
3.856, 95% CIs 1.321–11.26, P = 0.0135, log rank test).
Negative hormone receptor status, tumor size >2 cm, and
high nuclear YAP1 expression were significantly associated with
decreased DMFS, as assessed by univariate analysis (Table 2).
High nuclear YAP1 expression was still a significant determinant
of decreased DMFS after adjustment for hormone receptor
status, tumor size, and nuclear YAP1 expression by the Cox
proportional hazards model (HR 1.893, 95% CIs 1.009–3.552,
P = 0.047).
In the univariate Cox proportional hazard model, negative
hormone receptor status, high histologic grade, tumor size
> 2 cm, and high nuclear YAP1 expression were found to be
significant prognostic factors for OS (Supplementary Table 2).
However, in the multivariate analysis, nuclear YAP1 expressionFrontiers in Oncology | www.frontiersin.org 4was not a significant predictor of OS (Supplementary Table 2,
HR 1.576, 95% CIs 0.616–4.034, P = 0.343).
In validation cohort, high nuclear YAP1 expression was
significantly predictive of decreased DFS (Supplementary
Figure 1; HR, 3.208, 95% CIs 1.313–7.833, P = 0.0105, log
rank test). ER negativity, PR negativity, tumor size >2 cm,
lymph node metastasis, and high nuclear YAP1 expression
were significant factors in the multivariate analysis of DFS
(Supplementary Table 3). When adjusted for other factors,
high nuclear YAP1 expression was a significant factor in
reduced DFS (HR 2.112, 95% CIs 1.083–4.119, P = 0.028).
Prognostic Significance of Nuclear YAP1
Expression in TNBC Patients
The impact of nuclear YAP1 expression on survival and clinical
characteristics was evaluated in patients with TNBC (Supplementary
Table 4). Of the 146 TNBC patients, 80 (54.8%) had tumors with low
nuclear YAP1 expression, while 66 (45.2%) had tumors with high
nuclear YAP1 expression. In TNBC patients, the clinical
characteristics were not significantly affected by the level of nuclear
YAP1 expression. However, high nuclear YAP1 expression wasFIGURE 1 | Immunohistochemical analysis of nuclear YAP1 expression. Nuclear YAP1 expression was evaluated in high-power fields (400× magnification) by an
experienced pathologist. The samples were classified as negative (A), 1+ (B), 2+ (C), and 3+ (D), based on the intensity of YAP1 nuclear staining.February 2021 | Volume 11 | Article 609743
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5.386, P = 0.0367, log rank test). Lymph node metastasis and high
nuclear YAP1 expression were significant determinants of poor
DMFS in the univariate analysis (Supplementary Table 5).
Adjustment for significant factors in the univariate analysis
confirmed that high nuclear YAP1 expression was significantly
associated with DMFS (HR 2.329, 95% CIs 1.016–5.339, P = 0.046).DISCUSSION
In this study, the nuclear expression of YAP1 was evaluated in a
large number of breast cancer specimens, was found to be
significantly associated with the occurrence of distant
metastasis (HR 2.271, 95%CIs 1.109–4.650, P = 0.0249).
Furthermore, nuclear YAP1 expression was a strong
determinant of metastasis in TNBC (HR 2.384, 95%CIs 1.055–
5.386, P = 0.0367), an aggressive subtype of breast cancer. TheseFrontiers in Oncology | www.frontiersin.org 5findings indicate that targeted therapy for YAP1 may potentially
improve the survival outcomes, particularly metastasis, of the
patients with breast cancer.
The activation of YAP1, along with that of another
transcriptional co-activator TAZ, is associated with dysregulated
Hippo signaling (33, 34). YAP1 overexpression promotes EMT,
inhibits apoptosis, and induces growth factor-independent cell
proliferation. Based on these findings, it was speculated that YAP1
may play a role as a proto-oncogene (23). In addition, several
studies have reported a negative impact of YAP1 activation on the
survival of patients with gastric, colorectal, ovarian, bladder, and
non-small cell lung cancer (22, 29, 35–37).
Currently, the role of YAP1 in breast cancer remains
controversial. For instance, Lehn and colleagues reported that
YAP1 expression is inversely correlated with HG and tumor cell
proliferation, and that low YAP1 mRNA levels are associated
with decreased recurrence-free survival and tamoxifen-resistance
in luminal A subtype breast cancer (38). Also, some have
reported that YAP1 promotes cell proliferation, tumorigenesis,
EMT, and drug resistance, and is associated with TP53 mutation,
ER negativity, and poor survival (18, 39). However, several otherTABLE 1 | Clinical characteristics in relation to nuclear YAP1 expression.
YAP1-low,
n = 344 (%)
YAP1-high,
n = 111 (%)
P value
Age (year, mean ± SD) 50.78 ± 10.47 49.51 ± 9.50 0.256
HR <0.001
Positive 238 (69.2) 35 (31.5)
Negative 106 (30.8) 76 (68.5)
HER2a 0.301
Positive 50 (14.5) 12 (10.8)
Negative 290 (84.3) 99 (89.2)
Missing 4 (1.2) 0
HGa 0.005
I, II 223 (64.8) 54 (48.6)
III 115 (33.4) 52 (46.8)
Missing 6 (1.7) 5 (4.5)
Subtypea <0.001
Luminal/HER2(−) 210 (61.0) 33 (29.7)
HER2 (+) 50 (14.5) 12 (10.8)
TNBC 80 (23.3) 66 (59.9)
Missing 4 (1.2) 0
Tumor sizea 0.298
≤2 cm 174 (50.6) 50 (45.0)
>2 cm 169 (49.1) 61 (55.0)
Missing 1 (0.3) 0
Lymph node metastasisa 0.602
Negative 231 (67.2) 72 (64.9)
Positive 111 (32.3) 39 (35.1)
Missing 2 (0.6) 0
Ki67 (%)a 0.001
≤20% 258 (75.0) 62 (55.9)
>20% 74 (21.5) 40 (36.0)
Missing 12 (3.5) 9 (8.1)
Lymphovascular invasiona 0.413
Negative 268 (77.9) 81 (73.0)
Positive 55 (16.0) 21 (18.9)
Missing 21 (6.1)81 9 (8.1)




0.943SD, standard deviation; HR, hormone receptor; HER-2, human epidermal growth factor
receptor-2; HG, histological grade; TNBC, triple negative breast cancer; TILs, tumor-
infiltrating lymphocytes.
aPercentages calculated without missing values.A
B
FIGURE 2 | Kaplan-Meier survival curves of distant metastasis-free survival
(DMFS) and overall survival (OS) in relation to nuclear YAP1 expression.
Patients with high nuclear YAP1 expression exhibited poor DMFS and overall
survival (OS) (A, HR 2.271, 95% CI 1.109–4.650, P = 0.0249; B, HR 3.856,
95%CI 1.321–11.26; P = 0.0135, log-rank test, respectively).February 2021 | Volume 11 | Article 609743
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by YAP1 expression in breast cancer (39, 40), or YAP1 may in
fact act as a tumor suppressor (26, 41). Among the most of
previous studies mentioned above, the specific argument on
subcellular localization of YAP1 in previous studies were
unclear. Although Vlug et al. showed upregulated YAP1
expression in invasive lobular carcinoma, but its prognostic
impact was not evaluated (39). Kim et al. evaluated the
differential expression of YAP and phosphorylated YAP in the
each of molecular subtypes of breast cancer and found that
nuclear YAP expression was associated with shorter survival
(20). However, in previous study, nuclear YAP expression in
multivariate analysis did not have statistical significance. Given
that nuclear YAP1 expression is a surrogate marker of an
activated form of YAP1 (9), we focused on the nuclear YAP1
expression in this study, and found that nuclear YAP1 expression
is an independent prognostic predictor for distant metastasis,
particularly in the TNBC patients.
TNBC is simply defined as a breast cancer that satisfied the
ER, PR, and HER2 negativities, however it is not a uniform
subtype rather a complex heterogeneous collection of
molecularly different subtypes (42). Unlike hormone receptor-
positive type or HER2-type breast cancer, there is currently
limited therapeutic targets for TNBC, Although immuneFrontiers in Oncology | www.frontiersin.org 6checkpoint inhibitors are now applied in TNBC in combination
with chemotherapy (43, 44), demanding on targeted therapy is still
existed, and YAP1 could be the one of candidate of potential
therapeutic target.
Our study has several limitations. First, it was a retrospective
study. Second, the TNBC subtype was overrepresented due to
selection bias during sample collection. Third, TMA slide
staining may underestimate the rate of YAP1 positivity
compared to whole-slide examination. Although our study is
difficult to compare with previous IHC studies (20, 26, 38, 40, 41,
45), as these did not clarify whether the employed antibodies
were specific for phosphorylated YAP1, nor was the intracellular
localization of the antigen established, we specifically examined
the nuclear YAP1 expression and confirmed its prognostic
effect. In our study, no correlations were found between
cytosolic YAP1 staining and survival (data not shown). Despite
these limitations, the results demonstrated that nuclear YAP1
expression was a clinical prognostic factor in breast cancer,
especially TNBC.
In conclusion, we suggested that nuclear YAP1 expression is a
clinical prognostic factor for breast cancer. In addition, YAP1 is a
potentially valuable therapeutic target for patients with breast
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